113 related articles for article (PubMed ID: 28944496)
1. The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.
Nesbitt H; Worthington J; Errington RJ; Patterson LH; Smith PJ; McKeown SR; McKenna DJ
Prostate; 2017 Nov; 77(15):1539-1547. PubMed ID: 28944496
[TBL] [Abstract][Full Text] [Related]
2. Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.
Nesbitt H; Byrne NM; Williams SN; Ming L; Worthington J; Errington RJ; Patterson LH; Smith PJ; McKeown SR; McKenna DJ
Clin Cancer Res; 2017 Apr; 23(7):1797-1808. PubMed ID: 27697998
[No Abstract] [Full Text] [Related]
3. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
[TBL] [Abstract][Full Text] [Related]
4. Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
Eskra JN; Schlicht MJ; Bosland MC
Prostate; 2019 Feb; 79(2):223-233. PubMed ID: 30345530
[TBL] [Abstract][Full Text] [Related]
5. Combining Desmopressin and Docetaxel for the Treatment of Castration-Resistant Prostate Cancer in an Orthotopic Model.
Bass R; Roberto D; Wang DZ; Cantu FP; Mohamadi RM; Kelley SO; Klotz L; Venkateswaran V
Anticancer Res; 2019 Jan; 39(1):113-118. PubMed ID: 30591447
[TBL] [Abstract][Full Text] [Related]
6. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
7. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
[TBL] [Abstract][Full Text] [Related]
8. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
[TBL] [Abstract][Full Text] [Related]
9. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
10. Redox-responsive nanoparticles enhance radiation therapy by altering multifaceted radio-resistance mechanisms in human castration-resistant prostate cancer cells and xenografts.
Lip H; Amini MA; Zetrini A; Cai P; Abbasi AZ; Bristow RG; Rauth AM; Wu XY
Radiother Oncol; 2022 May; 170():213-223. PubMed ID: 35227733
[TBL] [Abstract][Full Text] [Related]
11. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.
Lalani AS; Alters SE; Wong A; Albertella MR; Cleland JL; Henner WD
Clin Cancer Res; 2007 Apr; 13(7):2216-25. PubMed ID: 17404106
[TBL] [Abstract][Full Text] [Related]
12. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
13. Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs).
Smith PJ; McKeown SR; Patterson LH
IUBMB Life; 2023 Jan; 75(1):40-54. PubMed ID: 35499745
[TBL] [Abstract][Full Text] [Related]
14. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
[TBL] [Abstract][Full Text] [Related]
15. Salicylate enhances the response of prostate cancer to radiotherapy.
Broadfield LA; Marcinko K; Tsakiridis E; Zacharidis PG; Villani L; Lally JSV; Menjolian G; Maharaj D; Mathurin T; Smoke M; Farrell T; Muti P; Steinberg GR; Tsakiridis T
Prostate; 2019 Apr; 79(5):489-497. PubMed ID: 30609074
[TBL] [Abstract][Full Text] [Related]
16. The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.
Trédan O; Garbens AB; Lalani AS; Tannock IF
Cancer Res; 2009 Feb; 69(3):940-7. PubMed ID: 19176397
[TBL] [Abstract][Full Text] [Related]
17. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
Saggar JK; Tannock IF
Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
[TBL] [Abstract][Full Text] [Related]
18. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
[No Abstract] [Full Text] [Related]
19. Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.
Cardillo I; Spugnini EP; Galluzzo P; Contestabile M; Dell'Anna ML; Picardo M; Crispi S; Calogero RA; Piccolo MT; Arigoni M; Cantarella D; Boccellino M; Quagliuolo L; Ferretti G; Carlini P; Felici A; Boccardo F; Cognetti F; Baldi A
Future Oncol; 2013 Sep; 9(9):1375-88. PubMed ID: 23980684
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
